Press releases | UCB
UCB's Global Corporate Website

This section is intended for media and financial analysts

Search Press releases

18 May 2022

Transparency notification Wellington

Read More
13 May 2022

Disposal of own shares

Read More
13 May 2022

Update on U.S. FDA Review of Biologics License Application (BLA) for bimekizumab

Read More
10 May 2022

UCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis

Read More
2 May 2022

JAMA Neurology Publishes Phase 3 Study Results on the Efficacy and Safety of FINTEPLA[®]▼(fenfluramine) Oral Solution for the treatment of seizures associated with Lennox-Gastaut Syndrome (LGS)

Read More
28 Apr 2022

UCB’s General Meeting of Shareholders 2022

Read More

Stay up-to-date on the latest news and information from UCB

Subscribe